




RealRate

PHARMACEUTICAL 2025

Xencor Inc
Rank 60 of 225



The relative strengths and weaknesses of Xencor Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xencor Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Xencor Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 303%, being 88% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	577,601
Cost of Goods Sold	0
Intangible Assets	18,485
Liabilities, Current	87,432
Liabilities, Non-Current	180,497
Other Assets	296,059
Other Compr. Net Income	1,968
Other Expenses	1,617
Other Liabilities	9,990
Other Net Income	-56,515
Other Revenues	110,493
Property and Equipment	59,800
Research and Development	227,686
Selling, General and Administrative Expense	61,215

Output Variable	Value in 1000 USD
Assets	951,945
Liabilities	277,919
Expenses	290,518
Revenues	110,493
Stockholders Equity	674,026
Net Income	-236,540
Comprehensive Net Income	-235,556
BaseVar	844,679
ECR before Limited Liability	201%
Economic Capital Ratio	303%